Table 2 of Gregory-Evans, Mol Vis 2009; 15:962-973.

Table 2. GDNF concentrations in vitreous and serum samples

Sample
time
point		 Wild-Type Untreated S334ter
Serum
(pg/ml)		 Vitreous
(pg/ml)		 Serum
(pg/ml)		 Vitreous
(pg/ml)
P50 12.8±1.6 21.3±19.4 23.5±3.8 16.5±7.8
P70 16.8±5.2 18.5±6.9 21.4±3.4 19.9±8.7
P90 14.0±4.1 3.8±1.0 28.5±11.0 9.2±10.1






Control S334ter Treated S334ter

Serum
(pg/ml)		 Vitreous
(pg/ml)		 Serum
(pg/ml)		 Vitreous
(pg/ml)
P50 29.4±4.9 18.3±7.2 *337.0±8.0 107.8±30.2**
P70 32.6±5.8 11.4±3.7 *333.0±79.8 181.1±32.1**
P90 22.1±7.2 14.2±6.3 *272.0±35.5 222.2±24.0**

Wild-type glial-derived neurotrophic factor (GDNF) levels in the serum and vitreous were compared to TgN S334ter treated (GDNF-secreting mouse embryonic stem cells), TgN S334ter control (mouse embryonic stem cells only), or untreated S334ter rats that were assessed at P50, P70, and P90 (n=3/time point). Data are presented as mean±SEM. The increase in serum (*p<0.001) or vitreous (**p<0.01) GDNF levels in treated animals compared to control mES cell injections is significant.

Gregory-Evans, Mol Vis 2009; 15:962-973. http://www.molvis.org/molvis/v15/a101

©2009 Molecular Vision http://www.molvis.org/molvis/

ISSN 1090-0535